dinn/iStock via Getty Images bluebird bio ( NASDAQ: BLUE ) is set to reduce its approximately 25% of its workforce as part of a restructuring plan intended to optimize cost structure. The restructuring is expected to result in a 20% reduction in cash operating expenses when fully realized.
Back to Health Page
